PARIS, November 28 ExonHit-Therapeutics
PARIS, November 28 /PRNewswire-FirstCall/ -- ExonHit Therapeutics S.A.
(Alternext: ALEHT), a drug and diagnostic discovery company, announces today
the availability of its new SpliceArray(TM) for use in studying mouse models
of human disease. These SpliceArray(TM) products help our clients accelerate
and refine their therapeutic target discovery and validation efforts. Using
our high resolution expression profiling analysis, we identify novel
transcripts coding for new protein variants that may be involved in various
genetic disorders such as oncology, central nervous system, or immune system
disorders. This mouse SpliceArray(TM) products represent the achievement of
more two years of work by our R&D team after the launch of the Human genome
SpliceArray(TM) in 2007 and the rat genome SpliceArray(TM) earlier this year.
"ExonHit has added another important species to its target discovery
services portfolio. This addition will expand our ability to service
scientists who use the mouse as a disease model, as well as our own discovery
programs for novel therapeutic targets and biomarkers," said John R.
Jaskowiak, Executive Vice President of Molecular Diagnostics and Genomics
Services at ExonHit Therapeutics.
"These new Mouse SpliceArray(TM) products will further accelerate the
understanding of mechanism of action and ultimately boost the discovery and
validation of new therapeutics for ExonHit, using the Mouse as a disease
model system, especially in the fields of oncology and CNS disease; this
unique approach enabling to save months of preclinical development time,"
stated Loic Maurel, Chairman of the Executive Board of ExonHit Therapeutics.
About ExonHit Therapeutics
http://www.exonhit.com
ExonHit Therapeutics is the world's leader in the analysis of alternative
RNA splicing, a process which when deregulated plays a key role in the onset
of various diseases.
ExonHit has a multi-component commercial strategy to capture the maximum
value from its leadership in alternative splicing. The Company is already
generating revenues from a new generation of microarrays, SpliceArrayTM
family of products, that enable life science researchers to detect crucial
disease-associated information. These products are marketed worldwide in
conjunction with Agilent and Affymetrix. In the field of diagnostics, ExonHit
has a major collaboration with bioMerieux to develop completely novel
predictive blood-based cancer diagnostics, which could play a key role in
improving the treatment of breast cancer and other major cancers.
In parallel, ExonHit is developing its own therapeutic pipeline in the
field of neurodegenerative diseases and cancer. The Company has advanced drug
candidates into clinical trials and is evaluating several promising
pre-clinical compounds. ExonHit also has a strategic partnership with
Allergan, to discover and develop new therapeutics in the areas of pain,
neurological diseases and ophthalmology. This collaboration provides on-going
research funding to ExonHit.
Founded in 1997, ExonHit is headquartered in Paris, France and has a U.S.
facility in Gaithersburg, Maryland. The Company is listed on Alternext of
Euronext Paris (ticker: ALEHT; ISIN: FR0004054427) since November 17, 2005.
This press release includes only summary information and does not purport
to be comprehensive. The projections, forecast and estimates of ExonHit
Therapeutics which may be contained herein are for illustrative purposes only
and are based on management's current views and assumptions. Such
projections, forecast and estimates involve known and unknown risks and
uncertainties, as described at Section 4.2 "Facteurs de risque" (Risk
Factors) of the Document de Base available on ExonHit Therapeutics' website
(http://www.exonhit.com), that may cause actual results, performance or
events to differ materially from those anticipated in the summary information.
In addition, ExonHit Therapeutics, its shareholders, and its affiliates,
directors, officers, advisors and employees have not verified the accuracy
of, and make no representations or warranties in relation to, statistical
data or predictions contained in this press release that were taken or
derived from third party sources or industry publications, and such
statistical data and predictions are used in this press release for
information purposes only.
Finally, this press release may be drafted in the French and English
languages. In an event of differences between the texts, the French language
version shall prevail.
SOURCE ExonHit Therapeutics SA
